SLC5A2 and Hepatic steatosis: A recent preclinical study using a mouse model of type 2 diabetes showed that a combination of the SGLT-2 inhibitor ipragliflozin plus pioglitazone significantly improved multiple NASH parameters, including hyperglycemia, insulin resistance, hyperlipidemia and liver injury (hepatic steatosis and fibrosis).